JP2009502961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502961A5 JP2009502961A5 JP2008524206A JP2008524206A JP2009502961A5 JP 2009502961 A5 JP2009502961 A5 JP 2009502961A5 JP 2008524206 A JP2008524206 A JP 2008524206A JP 2008524206 A JP2008524206 A JP 2008524206A JP 2009502961 A5 JP2009502961 A5 JP 2009502961A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- deuterium
- compound
- polymorph
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000651 prodrug Substances 0.000 claims 12
- 229940002612 prodrugs Drugs 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 9
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- -1 or a hydrate Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003247 decreasing Effects 0.000 claims 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 208000006673 Asthma Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010006451 Bronchitis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010062641 Female sexual arousal disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010061173 Gastrointestinal motility disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010034636 Peripheral vascular disease Diseases 0.000 claims 1
- 206010034800 Phaeochromocytoma Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 201000001068 Prinzmetal angina Diseases 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 206010038436 Renal failure acute Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000005485 Thrombocytosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 238000007889 carotid angioplasty Methods 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000000522 chronic kidney disease Diseases 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000004720 fertilization Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 201000005857 malignant hypertension Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 200000000009 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Claims (10)
- X1及びX2は同時に重水素である、請求項1に記載の化合物又はプロドラッグ、又はそのプロドラッグの塩、又はその水和物、溶媒和物、又は多形体。
- 重水素で置換されない水素原子すべては、天然の同位元素の存在度にて存在する、請求項1又は2に記載の化合物。
- 有効量の請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体、及び薬学上許容可能なキャリアを含む組成物。
- 勃起不全、安定、不安定及び異型の狭心症、高血圧症、肺高血圧症、慢性閉塞性肺疾患、急性呼吸窮迫症候群、悪性高血圧症、褐色細胞腫、鬱血性心不全、急性腎不全、慢性腎不全、アテローム性硬化症、血管の開放性が低下した状態、末梢血管疾患、血管障害、血小板血症、炎症性疾患、心筋梗塞、卒中、気管支炎、慢性喘息、アレルギー性喘息、アレルギー性鼻炎、緑内障、消化性潰瘍、消化管運動性障害、経皮経管冠動脈又は頚動脈血管形成後、バイパス手術後の移植狭窄、骨粗鬆症、早産陣痛、良性の前立腺肥大、及び刺激性腸症候群、男性のヒト及び動物における勃起不全、並びに女性における女性性的興奮障害、卵子との受精を促進するための精子数の減少、インスリン耐性の低下、濾胞の増殖の刺激から選ばれる疾患又は障害に罹っている又はそれに感受性である対象の治療に用いられる請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体を含有する剤。
- 線維症を含む症状の予防又は治療に用いられる請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体を含有する剤。
- 脊髄損傷を負っている患者における疼痛又は痙縮の緩和に用いられる請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体を含有する剤。
- 勃起不全の緩和又は予防に用いられる、請求項5に記載の剤。
- 重水素で置換されない水素原子すべて及び炭素原子すべては、天然の同位元素の存在度にて存在する、請求項9に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70361205P | 2005-07-29 | 2005-07-29 | |
US70357005P | 2005-07-29 | 2005-07-29 | |
PCT/US2006/029461 WO2007016361A2 (en) | 2005-07-29 | 2006-07-28 | Novel pharmaceutical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009502961A JP2009502961A (ja) | 2009-01-29 |
JP2009502961A5 true JP2009502961A5 (ja) | 2009-09-10 |
Family
ID=37709213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008524206A Pending JP2009502961A (ja) | 2005-07-29 | 2006-07-28 | 新規な医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070037815A1 (ja) |
EP (2) | EP2324886A1 (ja) |
JP (1) | JP2009502961A (ja) |
KR (1) | KR20080047375A (ja) |
AU (1) | AU2006275702A1 (ja) |
BR (1) | BRPI0615972A2 (ja) |
CA (1) | CA2616366A1 (ja) |
WO (1) | WO2007016361A2 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7863274B2 (en) * | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
US9012454B2 (en) | 2005-12-09 | 2015-04-21 | Mayo Foundation For Medical Education And Research | Sexual dysfunction |
US20090291958A1 (en) * | 2006-06-08 | 2009-11-26 | Auspex Pharmaceuticals, Inc. | Substituted PDE5 inhibitors |
MX2009003941A (es) | 2006-10-20 | 2009-04-24 | Concert Pharmaceuticals Inc | Derivados de 3-(dihidro-1h-pirazolo[4,3-d]pirimidin-5-il)-4-propox ibencenosulfonamida y metodos de uso. |
US8080549B2 (en) | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
US8071596B2 (en) | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
US20080194529A1 (en) * | 2007-02-12 | 2008-08-14 | Auspex Pharmaceuticals, Inc. | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS |
AU2008247805A1 (en) * | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Naphthyl(ethyl) acetamides |
US20080319086A1 (en) * | 2007-06-20 | 2008-12-25 | Protia, Llc | Deuterium-enriched salmeterol |
AU2008299921B2 (en) * | 2007-09-13 | 2012-03-01 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
WO2009099620A1 (en) * | 2008-02-04 | 2009-08-13 | Concert Pharmaceuticals Inc. | 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
HUP0900231A2 (hu) * | 2009-04-16 | 2010-11-29 | Hyd Rakkutato Es Gyogyszerfejlesztoe Kft | Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására |
JP2012531433A (ja) * | 2009-06-25 | 2012-12-10 | メドリューション リミテッド | キナーゼ阻害剤としての置換複素環式化合物とその用法 |
EP2687854A1 (en) * | 2012-07-19 | 2014-01-22 | Chiron AS | Test kit for the quantitative determination of narcotic drugs |
GB201221032D0 (en) * | 2012-11-22 | 2013-01-09 | Mens Health Ltd | Method of treatment |
KR20150127249A (ko) | 2013-03-13 | 2015-11-16 | 보스톤 바이오메디칼, 인크. | 암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체 |
EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
CA3194562A1 (en) | 2014-07-29 | 2016-02-04 | Shenzhen Hightide Biopharmaceutical, Ltd. | Berberine-ursodeoxycholic salt, method of preparation and application therof |
AU2015399642B2 (en) * | 2015-06-26 | 2020-04-09 | Chongqing Dikang Erle Pharma Co. Ltd. | Novel phosphodiesterase type-5 inhibitor and application thereof |
CN109180580B (zh) | 2016-02-28 | 2021-01-12 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的杂芳基化合物及包含该化合物的组合物及其用途 |
JP6969800B2 (ja) | 2016-05-04 | 2021-11-24 | ジェノシアンス ファルマ | 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体 |
EP3456328A4 (en) | 2016-05-10 | 2020-02-26 | Shenzhen Hightide Biopharmaceutical., Ltd. | COMPOSITION AND USE AND PHARMACEUTICAL PREPARATION THEREOF |
CN108864077B (zh) | 2017-05-12 | 2020-05-22 | 深圳君圣泰生物技术有限公司 | 小檗碱有机酸盐的固体形式及其制备方法 |
WO2019046163A1 (en) | 2017-08-28 | 2019-03-07 | Zhihong Chen | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND ASSOCIATED THERAPEUTIC METHODS |
WO2019099651A1 (en) * | 2017-11-16 | 2019-05-23 | Agios Pharmaceuticals, Inc. | Methods of using deuterated pyruvate kinase activators |
WO2019168999A1 (en) * | 2018-02-28 | 2019-09-06 | Ferro Therapeutics, Inc. | Compounds with ferroptosis inducing activity and methods of their use |
BR112021008128A2 (pt) | 2018-11-01 | 2021-08-03 | Lynk Pharmaceuticals Co. Ltd. | inibidores de janus quinase 1 tricíclicos, e composições e métodos dos mesmos |
WO2020146845A1 (en) | 2019-01-11 | 2020-07-16 | University Of Rochester | Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a |
CN117462549A (zh) | 2019-02-01 | 2024-01-30 | 康威(广州)生物科技有限公司 | 咪唑并喹啉胺衍生物、及其药物组合物和应用 |
CN114616234B (zh) | 2019-02-07 | 2024-04-12 | 康威(广州)生物科技有限公司 | 磷咪唑并喹啉胺衍生物、及其药物组合物和应用 |
US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
WO2021062307A1 (en) * | 2019-09-25 | 2021-04-01 | Intra-Cellular Therapies, Inc. | Novel methods |
CN114929284A (zh) | 2019-10-04 | 2022-08-19 | 西根公司 | 喜树碱肽缀合物 |
US20230340491A1 (en) | 2020-04-22 | 2023-10-26 | University Of Rochester | Compositions and methods for treating metabolic and cardiovascular diseases |
CA3224994A1 (en) | 2021-06-22 | 2022-12-29 | Dana-Farber Cancer Institute, Inc. | (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110099A (en) | 1975-12-17 | 1978-08-29 | Eli Lilly And Company | Novel fluoroalkoxyphenyl-substituted nitrogen heterocycles |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
IT1291320B1 (it) | 1997-05-08 | 1999-01-07 | Borregaard Italia Spa | Procedimento per la preparazione di composti aromatici contenenti un sistema eterociclico |
CA2306837C (en) | 1997-10-28 | 2007-05-08 | Asivi, Llc. | Treatment of female sexual dysfunction |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
AU4800999A (en) | 1998-07-28 | 2000-02-21 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
AU4663100A (en) | 1999-04-30 | 2000-11-17 | Lilly Icos Llc | Treatment of female arousal disorder |
KR20060093355A (ko) | 1999-08-03 | 2006-08-24 | 릴리 아이코스 엘엘씨 | 베타-카르볼린 약학 조성물 |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
US7737147B2 (en) | 2000-07-27 | 2010-06-15 | Thomas Nadackal Thomas | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
US6892568B2 (en) | 2003-02-03 | 2005-05-17 | Honda Giken Kogyo Kabushiki Kaisha | Noise detection system and method |
ATE341327T1 (de) | 2001-02-28 | 2006-10-15 | Merck & Co Inc | Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten |
MXPA03007785A (es) | 2001-02-28 | 2003-12-08 | Merck & Co Inc | Derivados de piperidina acilados como agonistas del receptor de melanocortina 4. |
KR20030081520A (ko) | 2001-03-14 | 2003-10-17 | 오노 야꾸힝 고교 가부시키가이샤 | Ep1 안타고니스트를 유효 성분으로서 함유하는 울병의치료제 |
CA2441792C (en) * | 2001-04-25 | 2010-08-03 | Lilly Icos Llc | Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction |
CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
LV12979B (en) | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
EP1461022A2 (en) | 2001-12-17 | 2004-09-29 | ALTANA Pharma AG | Use of selective pde5 inhibitors for treating partial and global respiratory failure |
US20050014848A1 (en) | 2002-01-23 | 2005-01-20 | Pfizer Inc. | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
US20030181461A1 (en) | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
US20030235609A1 (en) | 2002-01-25 | 2003-12-25 | Lautt Wilfred Wayne | Use of cholinesterase antagonists to treat insulin resistance |
US7091207B2 (en) | 2002-05-22 | 2006-08-15 | Virginia Commonwealth University | Method of treating myocardial infarction with PDE-5 inhibitors |
US20040077624A1 (en) | 2002-05-23 | 2004-04-22 | Pfizer Inc. | Novel combination |
US20040132731A1 (en) | 2002-06-26 | 2004-07-08 | Fox David Nathan Abraham | Novel combination |
US20040092522A1 (en) | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
US20050070969A1 (en) | 2002-09-06 | 2005-03-31 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by electrical stimulation and the delivery of drugs to the sacral and pudendal nerves |
US7369894B2 (en) | 2002-09-06 | 2008-05-06 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves |
US7427280B2 (en) | 2002-09-06 | 2008-09-23 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues |
US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
US8133903B2 (en) | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
US20040180958A1 (en) | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
GB0230025D0 (en) | 2002-12-23 | 2003-01-29 | Pfizer Ltd | Novel pharmaceuticals |
WO2004069167A2 (en) | 2003-01-31 | 2004-08-19 | Nastech Pharmaceutical Company Inc. | Method and compositions for treating male infertility |
JP4533590B2 (ja) | 2003-02-28 | 2010-09-01 | ファイザー株式会社 | 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物 |
AR043434A1 (es) | 2003-03-03 | 2005-07-27 | Merck & Co Inc | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos |
PA8597401A1 (es) | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
US20040186046A1 (en) | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
BRPI0409229A (pt) | 2003-04-01 | 2006-03-28 | Applied Research Systems | inibidores das fosfodiesterases na infertilidade |
BRPI0411347A (pt) | 2003-06-10 | 2006-07-11 | Pfizer | combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia |
US20050101608A1 (en) | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
US7745630B2 (en) * | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
JP2007517049A (ja) | 2003-12-29 | 2007-06-28 | マクデビット、ジェイソン | 再発性病状を治療するための組成物および方法 |
-
2006
- 2006-07-28 EP EP11155798A patent/EP2324886A1/en not_active Withdrawn
- 2006-07-28 BR BRPI0615972-9A patent/BRPI0615972A2/pt not_active Application Discontinuation
- 2006-07-28 KR KR1020087004869A patent/KR20080047375A/ko not_active Application Discontinuation
- 2006-07-28 EP EP06788821A patent/EP1909576A4/en not_active Withdrawn
- 2006-07-28 JP JP2008524206A patent/JP2009502961A/ja active Pending
- 2006-07-28 WO PCT/US2006/029461 patent/WO2007016361A2/en active Application Filing
- 2006-07-28 AU AU2006275702A patent/AU2006275702A1/en not_active Abandoned
- 2006-07-28 CA CA002616366A patent/CA2616366A1/en not_active Abandoned
- 2006-07-31 US US11/498,305 patent/US20070037815A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009502961A5 (ja) | ||
JP7169412B2 (ja) | 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体 | |
AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
JP2009502963A5 (ja) | ||
JP6345645B2 (ja) | 横隔膜機能を向上させるための方法 | |
JP2010533203A5 (ja) | ||
JP4477097B2 (ja) | 中枢神経系障害の治療のための(2s)−(4e)−n−メチル−5−[3−(5−イソプロポキシピリジン)イル]−4−ペンテン−2−アミンの多形形態 | |
US20090181968A1 (en) | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | |
TW201305169A (zh) | 7-環戊基-2-(5-哌□-1-基-吡啶-2-基胺基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲醯胺之鹽類及其製備方法 | |
RU2008100933A (ru) | ПИРРОЛО[2,3-b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ | |
JP2017522276A5 (ja) | ||
JP2008510762A5 (ja) | ||
JP2013529647A5 (ja) | ||
JP2013532162A5 (ja) | 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および/または予防のためのその使用 | |
TW201004941A (en) | Alpha7 nicotinic acetylcholine receptor inhibitors | |
TW200900068A (en) | Novel N,N'-2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors | |
JP2022166179A (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
JP2007051155A (ja) | ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体 | |
JP5710490B2 (ja) | (r)−5−((e)−2−(ピロリジン−3−イルビニル)ピリミジンの合成および新規の塩形態 | |
JP2007523206A (ja) | Cb2受容体モジュレーターとしてのピリジン誘導体およびその使用 | |
RU2004133811A (ru) | Новые соединения | |
JP2019508385A (ja) | テネリグリプチンのシュウ酸塩およびその溶媒和物、中間体、その調製方法およびマーカー | |
JP2007507464A (ja) | 新規のアミノピリジン誘導体 | |
CN114206836B (zh) | 新型吡咯化合物 | |
JPWO2019220390A5 (ja) |